Literature DB >> 22179855

Cooperation between Polycomb and androgen receptor during oncogenic transformation.

Jonathan C Zhao1, Jianjun Yu, Christine Runkle, Longtao Wu, Ming Hu, Dayong Wu, Jun S Liu, Qianben Wang, Zhaohui S Qin, Jindan Yu.   

Abstract

Androgen receptor (AR) is a hormone-activated transcription factor that plays important roles in prostate development and function, as well as malignant transformation. The downstream pathways of AR, however, are incompletely understood. AR has been primarily known as a transcriptional activator inducing prostate-specific gene expression. Through integrative analysis of genome-wide AR occupancy and androgen-regulated gene expression, here we report AR as a globally acting transcriptional repressor. This repression is mediated by androgen-responsive elements (ARE) and dictated by Polycomb group protein EZH2 and repressive chromatin remodeling. In embryonic stem cells, AR-repressed genes are occupied by EZH2 and harbor bivalent H3K4me3 and H3K27me3 modifications that are characteristic of differentiation regulators, the silencing of which maintains the undifferentiated state. Concordantly, these genes are silenced in castration-resistant prostate cancer rendering a stem cell-like lack of differentiation and tumor progression. Collectively, our data reveal an unexpected role of AR as a transcriptional repressor inhibiting non-prostatic differentiation and, upon excessive signaling, resulting in cancerous dedifferentiation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22179855      PMCID: PMC3266039          DOI: 10.1101/gr.131508.111

Source DB:  PubMed          Journal:  Genome Res        ISSN: 1088-9051            Impact factor:   9.043


  30 in total

1.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.

Authors:  Jindan Yu; Jianjun Yu; Ram-Shankar Mani; Qi Cao; Chad J Brenner; Xuhong Cao; Xiaoju Wang; Longtao Wu; James Li; Ming Hu; Yusong Gong; Hong Cheng; Bharathi Laxman; Adaikkalam Vellaichamy; Sunita Shankar; Yong Li; Saravana M Dhanasekaran; Roger Morey; Terrence Barrette; Robert J Lonigro; Scott A Tomlins; Sooryanarayana Varambally; Zhaohui S Qin; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

2.  DHT selectively reverses Smad3-mediated/TGF-beta-induced responses through transcriptional down-regulation of Smad3 in prostate epithelial cells.

Authors:  Kyung Song; Hui Wang; Tracy L Krebs; Bingcheng Wang; Thomas J Kelley; David Danielpour
Journal:  Mol Endocrinol       Date:  2010-08-25

Review 3.  Minireview: Alternative activation pathways for the androgen receptor in prostate cancer.

Authors:  Kristin R Lamont; Donald J Tindall
Journal:  Mol Endocrinol       Date:  2011-03-24

4.  Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer.

Authors:  Derek S Welsbie; Jin Xu; Yu Chen; Laetitia Borsu; Howard I Scher; Neal Rosen; Charles L Sawyers
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

5.  Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor.

Authors:  Biaoyang Lin; Jun Wang; Xu Hong; Xiaowei Yan; Daehee Hwang; Ji-Hoon Cho; Danielle Yi; Angelita G Utleg; Xuefeng Fang; Dustin E Schones; Keji Zhao; Gilbert S Omenn; Leroy Hood
Journal:  PLoS One       Date:  2009-08-11       Impact factor: 3.240

6.  Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells--identification of a novel androgen response element.

Authors:  Marilena Lanzino; Diego Sisci; Catia Morelli; Cecilia Garofalo; Stefania Catalano; Ivan Casaburi; Claudia Capparelli; Cinzia Giordano; Francesca Giordano; Marcello Maggiolini; Sebastiano Andò
Journal:  Nucleic Acids Res       Date:  2010-04-26       Impact factor: 16.971

7.  Nucleosome dynamics define transcriptional enhancers.

Authors:  Housheng Hansen He; Clifford A Meyer; Hyunjin Shin; Shannon T Bailey; Gang Wei; Qianben Wang; Yong Zhang; Kexin Xu; Min Ni; Mathieu Lupien; Piotr Mieczkowski; Jason D Lieb; Keji Zhao; Myles Brown; X Shirley Liu
Journal:  Nat Genet       Date:  2010-03-07       Impact factor: 38.330

8.  HPeak: an HMM-based algorithm for defining read-enriched regions in ChIP-Seq data.

Authors:  Zhaohui S Qin; Jianjun Yu; Jincheng Shen; Christopher A Maher; Ming Hu; Shanker Kalyana-Sundaram; Jindan Yu; Arul M Chinnaiyan
Journal:  BMC Bioinformatics       Date:  2010-07-02       Impact factor: 3.169

9.  The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer.

Authors:  J Yu; Q Cao; J Yu; L Wu; A Dallol; J Li; G Chen; C Grasso; X Cao; R J Lonigro; S Varambally; R Mehra; N Palanisamy; J Y Wu; F Latif; A M Chinnaiyan
Journal:  Oncogene       Date:  2010-07-12       Impact factor: 9.867

10.  Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Authors:  Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

View more
  70 in total

1.  Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression.

Authors:  Bing Song; Su-Hong Park; Jonathan C Zhao; Ka-Wing Fong; Shangze Li; Yongik Lee; Yeqing A Yang; Subhasree Sridhar; Xiaodong Lu; Sarki A Abdulkadir; Robert L Vessella; Colm Morrissey; Timothy M Kuzel; William Catalona; Ximing Yang; Jindan Yu
Journal:  J Clin Invest       Date:  2018-12-18       Impact factor: 14.808

2.  Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.

Authors:  Pei-Chun Lin; Ya-Lin Chiu; Samprit Banerjee; Kyung Park; Juan Miguel Mosquera; Eugenia Giannopoulou; Pedro Alves; Ashutosh K Tewari; Mark B Gerstein; Himisha Beltran; Ari M Melnick; Olivier Elemento; Francesca Demichelis; Mark A Rubin
Journal:  Cancer Res       Date:  2012-12-11       Impact factor: 12.701

Review 3.  Molecular pathogenesis and progression of prostate cancer.

Authors:  Randy Schrecengost; Karen E Knudsen
Journal:  Semin Oncol       Date:  2013-06       Impact factor: 4.929

4.  ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer.

Authors:  Dong Han; Sujun Chen; Wanting Han; Shuai Gao; Jude N Owiredu; Muqing Li; Steven P Balk; Housheng Hansen He; Changmeng Cai
Journal:  Cancer Res       Date:  2019-08-23       Impact factor: 12.701

5.  Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment.

Authors:  Irene Marchesi; Luigi Bagella
Journal:  World J Clin Oncol       Date:  2016-04-10

6.  Polycomb-Mediated Disruption of an Androgen Receptor Feedback Loop Drives Castration-Resistant Prostate Cancer.

Authors:  Ka-Wing Fong; Jonathan C Zhao; Jung Kim; Shangze Li; Yeqing A Yang; Bing Song; Laure Rittie; Ming Hu; Ximing Yang; Bernard Perbal; Jindan Yu
Journal:  Cancer Res       Date:  2016-11-04       Impact factor: 12.701

Review 7.  EZH2: not EZHY (easy) to deal.

Authors:  Gauri Deb; Anup Kumar Singh; Sanjay Gupta
Journal:  Mol Cancer Res       Date:  2014-02-13       Impact factor: 5.852

8.  Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.

Authors:  Hong-Jian Jin; Jonathan C Zhao; Irene Ogden; Raymond C Bergan; Jindan Yu
Journal:  Cancer Res       Date:  2013-03-28       Impact factor: 12.701

9.  CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor.

Authors:  L Wu; C Runkle; H-J Jin; J Yu; J Li; X Yang; T Kuzel; C Lee; J Yu
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

10.  USP22 regulates oncogenic signaling pathways to drive lethal cancer progression.

Authors:  Randy S Schrecengost; Jeffry L Dean; Jonathan F Goodwin; Matthew J Schiewer; Mark W Urban; Timothy J Stanek; Robyn T Sussman; Jessica L Hicks; Ruth C Birbe; Rossitza A Draganova-Tacheva; Tapio Visakorpi; Angelo M DeMarzo; Steven B McMahon; Karen E Knudsen
Journal:  Cancer Res       Date:  2013-11-06       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.